The Impact of COVID-19 Lockdown on the Incidence of Type 1 DM and the Glycemic Control of Diabetic Children: Findings from a Teaching Hospital, Saudi Arabia

Mohammad Hussain Al-Qahtani¹, Fatimah Mousa Bukhamseen², Aqilah Taleb Al-Qassab², Abdullah Abdulsalam Yousef³, Bassam Hassan Awary³, Waleed Hamad Albuali³, Zainab Mohammed Alkhalifa³, Haneen Abdulsalam Yousef⁴

¹Department of Pediatrics, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, ²College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, ³Pediatic Endocrine Fellow, Eastern Health Cluster, Dammam, Saudi Arabia, ⁴Department of Family Medicine, College of Medicine, Imam Abdulrahman Bin Faisal university, Dammam, Saudi Arabia.

Address correspondence to: Mohammad Hussain Al-Qahtani, e-mail: mhqahtani@iau.edu.sa

Manuscript submitted May 25, 2022; resubmitted June 29, 2022; accepted July 27, 2022

OBJECTIVE: We evaluated glycemic control among T1DM pediatric patients attending the endocrinology pediatrics clinics at King Fahd Hospital of the University (KFHU) prior to and during COVID-19 restraining regulations. In addition, we assessed the trends and variations in the incidence of T1DM during 2017-2021, including the COVID-19 years by identifying newly diagnosed patients presenting to pediatrics emergency department (ED) in KFHU.

METHODS: To estimate the effect of COVID-19 on the incidence of T1DM, we identified newly diagnosed cases of T1DM among pediatric patients attending the ED during the years 2017-2021. The participants' data were collected through electronic medical records. Information collected included patient age, sex, and HbA1c readings. Three HbA1c readings of interest that were defined and collected are pre-COVID reading, in-COVID reading, and post-COVID reading.

RESULTS: The difference of female participants' readings was statistically non-significant (Z= -0.416, p = 0.678), with a pre- and post-COVID median of 10.70 (Q1= 9.00, Q3= 12.15), and 10.50 (Q1= 8.80, Q3= 12.35), respectively. In contrast, the difference was statistically significant among male participants (Z= -2.334, p = 0.02), with a pre- and post-COVID median of 10.20 (Q1= 8.70, Q3= 11.85), and 10.65 (Q1= 9.00, Q3= 12.70), respectively. There was a statistically significant increase in HbA1c of persons > 11 years old (Z= -2.471, p= 0.013), with a pre- and post-COVID median of 10.40 (Q1= 9.00, Q3= 12.10), and 10.90 (Q1= 9.00, Q3= 12.60), respectively. Conversely, persons ≤ 11 years old showed no statistically significant change in HbA1c (Z= -0.457, p= 0.648), with a pre- and post-COVID median of 10.45 (Q1= 9.00, Q3= 11.85), and 10.20 (Q1= 8.40, Q3= 12.075), respectively.

CONCLUSIONS: The number of visits to healthcare facilities dropped significantly during the COVID-19 pandemic, but the rate of newly diagnosed T1DM increased. There was a variable effect on HbA1c levels of those patients, which suggests that each demographic group in the population might have been affected differently by the pandemic. Future research should determine factors associated with better glycemic control and measures to sustain these changes the pandemic might have created.

Keywords: coronavirus · SARS-Cov-2 virus · COVID-19 · type I diabetes mellitus · glycemic control · teaching hospital

1. Introduction

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2 virus). It is a respiratory disease with variable manifestations ranging from asymptomatic to mild symptoms to more severe illness. Globally, governments implemented many measures to avoid the spread of the virus, thereby minimizing the burden on their countries [1,2].

The pandemic has transformed daily lives and continues to disrupt the everyday routines of societies.
According to World Health Organization, the total number of confirmed cases are over 515 million worldwide, of which 755,415 have been reported in Saudi Arabia [3]; the Saudi government imposed a lockdown order on March 25, 2020.

In 2020, the incidence of COVID-19 was reported less among pediatric patients and contributed to 8% of the daily reported cases [4]. However, since late December 2021, a spike in the incidence and hospitalization in the pediatric age group was noticed, especially for younger children who are ineligible for vaccination [5].

As the pandemic persists, new challenges keep emerging in healthcare related to the dynamics of managing acute and chronic diseases. One of the most prevalent chronic conditions worldwide that affects a wide range of age groups is diabetes mellitus [6]. Saudi Arabia has documented remarkably high numbers of type 1 diabetes mellitus (T1DM) among children and adolescents that puts it in the lead among countries in the Middle East and North Africa, with an estimated prevalence of 27,800 in 2019 [7]. As the COVID-19 pandemic situation entailed governments to impose several social restrictions, including the lockdown, a persistent demand is rising to understand the impact of these actions on such a vulnerable group.

The influence of COVID-19 on the glycemic control of diabetic patients has been discussed in the literature; however, it remains inconclusive. Many overlapping factors have been identified that could influence blood glucose levels throughout these different periods. For instance, increased parent care, as well as the drop in consumption of fast food, resulted in a decline of glycated hemoglobin (HbA1c) [8,9]. On the other hand, a decreased level of physical activity and limited access to healthcare services along with other factors had a negative impact on blood glucose level [10].

As the incidence of T1DM grows, the impact of COVID-19 restrictions on this population should be thoroughly investigated to be able to mitigate any potential negative consequences. The purpose of the study is to evaluate and analyze the glycemic control among T1DM pediatric patients attending the endocrinology pediatrics clinics at King Fahd Hospital of the University (KFHU) prior to and during COVID-19 restraining regulations. In addition, we assess the trends and variations in the incidence of T1DM during 2017-2021, including the COVID-19 years by identifying newly diagnosed patients presenting to pediatrics emergency department in KFHU.

2. Methods

This is a longitudinal observational retrospective study, which took place in the diabetic pediatrics clinics and the emergency department at King Fahd Hospital of the University (KFHU), a teaching hospital in Al-Khobar, Saudi Arabia. To estimate the effect of COVID-19 on the incidence of T1DM, we identified newly diagnosed cases of T1DM among pediatric patients attending the emergency department (ED) during the years 2017-2021. In our facility, once a patient’s diagnosis is established, a unique problem code is assigned to the patient’s electronic medical record which corresponds to the predefined ICD-9 codes available in the master repository of the system. Accordingly, we were able to identify all individuals who we under 18 years of age and labeled as T1DM (ICD-9 code 250.01) to be included in this study. The number of ED visits per year was obtained retrospectively through the register, and it served as the dominator in establishing the incidence rate. Simultaneously, the target population to assess the effects of COVID-19 pandemic on the control of T1DM included pediatric patients ≥ 2 years of age but < 18 years diagnosed with T1DM, who had attended any pediatric diabetes clinic, between the months of September 2019 and March of 2020. There are 3 pediatric diabetic clinics per week in our facility, taking place at different days of the week. Patients diagnosed with diabetes and < 18 years old are referred to the clinic through the ED or after general pediatric ward admission. An average of 6.4 patients are seen in each clinic.

The participants’ data were collected through electronic medical records. Information collected included patient age, sex, and HbA1c readings. Three HbA1c readings of interest that were defined and collected are pre-COVID reading, in-COVID reading, and post-COVID reading. The pre-lockdown reading is defined as any reading prior to lockdown to 3 months after the start of lockdown (March 9, 2020). When multiple pre-lockdown readings are available, the latest is considered. The in-lockdown reading is the earliest reading post 3 months from the start of lockdown. Finally, the post-lockdown reading is defined as the latest reading taken in 2021. Initially, a list of 270 patients who have visited the diabetic clinics between September 2019 and March 2020 were examined. Those who did not have a pre-COVID reading, had only one HbA1c reading, or whose HbA1c could not be reported due to a hemoglobin variant were excluded. A total of 203 participants were included in the analysis (Figure 1).

Data analysis was performed using the Statistical Package of Social Sciences (SPSS) version 26 (IBM Corp, Armonk, NY). Normality was examined using the Shapiro-Wilk test. Continuous variables were summarized as means ± standard deviation (SD) while categorical variables were summarized using frequency and percentages. A mixed ANOVA was used to test the

---

**Abbreviations:**

COVID-19  Coronavirus disease 2019  
SARS-CoV-2  Severe acute respiratory syndrome coronavirus 2  
T1DM  Type 1 diabetes mellitus  
KFHU  King Fahd hospital of the university  
ED  Emergency department  
SPSS  Statistical package for social sciences  
SD  Standard deviation
statistical significance of main and interaction effects of the independent variables on the HbA1c levels of the participants. For skewed data, Wilcoxon signed-rank tests was used. A p < 0.05 was considered statistically significant.

3. Results

3.1 Effect of COVID on T1DM incidence

A total of 940 patients with newly diagnosed T1DM occurred during the years spanning the study. Table 1 shows the annual incidence rate throughout the years of 2017-2021. Figure 2 shows the trend of the incidence rate.

3.2 Effect of COVID on HbA1c readings

Out of the 203 participants included in this study, 112 (55%) were females and 91 (45%) were males. The predominant age group included those > 11 years old, with only 72 being ≤ 11 years old. HbA1c was recorded at 3-time intervals. To assess the influence of COVID lockdown on the glycemic control, the participants HbA1c was examined and analyzed using 2 different models.

3.2.1 Two-point analysis

First, a 2-group analysis was done with all 203 participants included. The groups were sorted to pre-COVID readings and post-COVID readings, the latter including either in-lockdown or post-lockdown readings. The median pre-COVID and post-COVID HbA1c readings were 10.40 (Q₁ = 8.90, Q₃ = 11.90), and 10.50 (Q₁ = 8.90, Q₃ = 12.50), respectively. The results showed no statistically significant difference between pre- and post-COVID readings (Z = -1.759, p = 0.079). This was further analyzed by sex and age groups.

Wilcoxon signed-rank tests indicated that the difference of female participants' readings was statistically non-significant (Z = -0.416, p = 0.678), with

![Figure 1. Flowchart of included participants.]

![Figure 2. Trend of the annual incidence.](image-url)
a pre- and post-COVID median of 10.70 (Q1 = 9.00, Q3 = 12.10), and 10.90 (Q1 = 9.00, Q3 = 12.60), respectively. Females had higher readings overall, except for the post-lockdown period where males displayed higher HbA1c readings.

3.2.2 Three-point analysis

Data were then analyzed at 3 chronological points. The mean readings of pre-lockdown, in-lockdown, and post-lockdown periods were 10.574 (SD = 2.1954), 10.5818 (SD = 2.52848), and 10.5817 (SD = 2.41831), respectively. Females had higher readings overall, except for the post-lockdown period where males displayed higher HbA1c readings. As per the age distribution, those older than 11 years had a tendency toward higher HbA1c readings (Table 2).

Table 2. Mean HbA1c readings per gender and age distribution

|            | Age Group | HbA1c | HbA1c | HbA1c |
|------------|-----------|-------|-------|-------|
|            | Pre-COVID | In-COVID | Post-COVID |
| Males      | 10.4278   | 10.5611 | 10.6442 |
| Females    | 10.5708   | 10.6024 | 10.5280 |
| ≤ 11 years | 10.440    | 10.071  | 10.243  |
| > 11 years | 10.544    | 10.892  | 10.755  |

While disregarding any influence of time, the effect of sex was analyzed using a mixed ANOVA test, which showed no statistically significant difference in HbA1c between males and females [F(1,125) = 0.008, p = 0.930]. Meanwhile, the age effect on HbA1c readings, regardless of time influence, was statistically significant [F(1,125) = 4.993, p = 0.027]. The main effect of time on Hba1c levels was analyzed while adjusted for both sex and age in parallel fashion, and both results were non-significant [sex: F(1,74,217) = 1.86, p = 0.30; age: F(1,25,289.57), p = 0.559]. Likewise, there was no statistically significant interaction between time and sex on HbA1c levels [F(1,74,217) = 0.096, p = 0.889] and between age and time [F(3,92,289.57) = 1.693, p = 0.190].

4. Discussion

Over the course of the COVID-19 pandemic during the last 2 years, several papers have discussed its effect on diabetes development and control. In Saudi Arabia, there was an increase in the incidence of T1DM among pediatric patients during the pre-pandemic period [11,12]. However, these local trends have not been described and analyzed compared to the pandemic period. In our longitudinal observational retrospective study, we measured the annual incidence rate for 3 years prior to the COVID-19 pandemic and 2 years during the pandemic, revealing higher annual incidence rate in our institution during the COVID-19 outbreak – from 4.17 in 2019 to 8.39 and 6.00 per 1000 during 2020 and 2021, respectively.

Our results were consistent with international studies conducted to assess the incidence of pediatric T1DM during the COVID-19 pandemic and any changes in the pattern of development. A multicenter regional study in Northwest London that involved 5 in-patients centers reported a total number of 30 new-onset cases during April/May 2020 with an increase in 2 centers, but a constant rate in the other 3 centers [13]. Similarly, a cross-sectional study in San Diego collected data over a 12-month interval throughout the in-COVID period and compared their results with the annual incidence prior to COVID-19 pandemic. Higher rates of newly diagnosed T1DM were reported compared to the previous year, 189 and 119 respectively [14].

Meanwhile, many authors have speculated that the COVID-19 pandemic has had an influence on diabetic patients’ glycemic control. The lockdown situation in particular has created new circumstances for all populations that directly influence patients’ ability to control their well-being. However, literature concerning T1DM patients’ glycemic control is controversial. Several studies have concluded that the lockdown had a positive influence on glycemic control. The Fernandez et al study demonstrated a substantial improvement in HbA1c readings, particularly in those with a baseline higher than 8% [15]. Another study among Danish children attending diabetic clinics showed comparable results of HbA1c reduction in those with a baseline > 7.5%. Nevertheless, they also found those with a baseline HbA1c < 6.9% to have a marginal increase in their readings. In contrast to our finding of age being a factor influencing poor glycemic control regardless of time, they found that those older than 11 years demonstrated a significant reduction in HbA1c over time [16].

In comparison, other studies found that glycemic control measures became worse after the lockdown period. A Saudi study revealed that the lockdown was associated with a significant increase in the mean blood glucose level (200.45 ± 79.970) in comparison with pre-lockdown period (182.09 ± 76.68) [10]. This finding aligns with Hosomi et al’s study that described a significant worsening of HbA1c readings among T1DM patients in Kyoto, Japan [17]. Similar to our results, a study conducted at an urban pediatric teaching hospital in Texas found that increasing age was associated with higher HbA1c readings, although there was no difference between pre- and post-lockdown groups [18].

Our study has several limitations, because of its retrospective nature, not all glycemic control measures could be assessed. In addition, our findings are based on data collected from a teaching center, that serves an urban area. Therefore, it is possible that these data reflect the situation among those individuals for whom...
healthcare is more readily accessible. Furthermore, the pediatric endocrine clinics in our center were running virtually for almost 8 months during and after the lockdown, and the majority of patients tended to avoid attending healthcare centers in person to minimize exposure to COVID-19. This resulted in a lower rate of laboratory work-up for this population, and thus, limited the number of patients included in this study.

Our investigation was just a single center-based study so the results cannot be generalized to other settings; however, this encourages other large centers nationally as well as internationally to publish their results to determine many of the factors that might affect the incidence of T1DM and the glycemic control of diabetic children during the critical and unusual period of the COVID-19 era.

4.1 Conclusion

The number of visits to healthcare facilities dropped significantly during the COVID-19 pandemic; however, the rate of newly diagnosed T1DM markedly increased. The literature both locally and internationally is inconclusive concerning the influence of COVID-19 on glycemic control. In our study, the situation had a variable effect on HbA1c levels of those patients, which suggests that each demographic group in same population might have been affected differently by the pandemic. Future research should determine factors associated with better glycemic control and measures to sustain these changes the pandemic might have created. Furthermore, these findings might help healthcare providers plan for such exceptional situations to manage the T1DM children trying to keep their glycemic control on target levels.

Conflicts of interest statement: We declare no conflicts of interest regarding our manuscript.

Ethical approval: The Institutional Review Board (IRB) of Imam Abdulrahman Bin Faisal University approved this study (IRB-2021-01-202). The IRB waived the need for obtaining informed consent because of the retrospective nature of the study. Furthermore, data confidentiality was ensured following the Declaration of Helsinki principles. The data were dealt with in an anonymous manner to protect the participants’ privacy.

References

1. Coronavirus. World Health Organization. World Health Organization; [cited 2022Apr9]. Available from: https://www.who.int/health-topics/coronavirus#tab=tab_1
2. Nathan N, Prevost B, Sileo C, Richard N, Berdah L, Thouvenin G. The wide spectrum of covid-19 clinical presentation in children. Journal of Clinical Medicine 2020, 9(9):2950.
3. World Health Organization Coronavirus (COVID-19) Dashboard. World Health Organization; [cited 2022May10]. Available from: https://covid19.who.int/table
4. Alyami MH, Naser AY, Orabi MA, Alwafii H, Alyami HS. Epidemiology of covid-19 in the Kingdom of Saudi Arabia: An ecological study. Frontiers in Public Health 2020, 8:506.
5. Anesi J. Commentary: Effectiveness of two-dose vaccination with mrna Covid-19 vaccines against covid-19-associated hospitalizations among immunocompromised adults-nine states, January–September 2021. American Journal of Transplantation 2021, 22(1):304-5.
6. Aalaqeeil AA. Pediatric diabetes in Saudi Arabia: Challenges and potential solutions. A review article. International Journal of Pediatrics and Adolescent Medicine 2019, 6(4):125-30.
7. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: 2019. Available at: https://www.diabetesatlas.org
8. Di Dalmazi G, Maltoni G, Bongiorno C, Tucci L, Di Natale V, Moscatiello S. Comparison of the effects of lockdown due to covid-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study. BMJ Open Diabetes Research 2020, 8(2):e001664.
9. Lombardo F, Salzano G, Bombacci B, Basile P, Lucania G, Alibrandi A. Has covid-19 lockdown improved glycaemic control in pediatric patients with type 1 diabetes? an analysis of continuous glucose monitoring metrics. Diabetes Research and Clinical Practice 2021, 178:108988.
10. Agha AE, Alharbi RS, Almohammadi OA, Yousef SY, Sulimani AE, Alama RA. Impact of covid-19 lockdown on glycemic control in children and adolescents. Saudi Medical Journal 2021, 42(1):44-8.
11. Abduljabbar MA, Aljubeh JM, Amalraj A, Cherian MP. Incidence trends of childhood type 1 diabetes in eastern Saudi Arabia. Saudi Medical J 2010, 31(4):413-8.
12. Alotaibi A, Perry L, Gholizadeh L, Al-Gnami A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: An overview. Journal of Epidemiology and Global Health 2017, 7(4):211.
13. Unsworth R, Wallace S, Oliver N, Yeung S, Kshirsagar A, Naidu H. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020, 43(11):e170-71.
14. Gottesman B, Yu J, Tanaka C, Longhurst C, Kim J. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA Pediatrics 2022, 176(4):414.
15. Fernandez E, Cortazar A, Bellido V. Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diabetes Research and Clinical Practice 2020, 166:108348.
16. Kofood P, Timm S. The impact of COVID,ÅE19 lockdown on glycemic control and use of health services among children followed at a Danish diabetes clinic. Acta Paediatrica 2022, 111(2):368-75.
17. Hosomi Y, Munekawa C, Hashimoto Y, Okamura T, Takahashi F, Kawano R. The effect of COVID-19 pandemic on the lifestyle and glycemic control in patients with type 1 diabetes: a retrospective cohort study. Diabetology International 2022, 13(1):85-90.
18. Choudhary A, Adhikari S, White PC. Impact of the COVID-19 pandemic on management of children and adolescents with Type 1 diabetes. BMC Pediatrics 2022, 22(1):124.